Evaluation of clarithromycin on TNF-a serum level in patients with multiple sclerosis

Evaluation of clarithromycin on TNF-a serum level in patients with multiple sclerosis: A randomized, double-blind, crossover, placebo-controlled pilot study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100119003106N41

Enrollment

Registered

2020-08-08

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

MS patients were randomly assigned to receive either clarithromycin (500mg) or placebo tablets twice daily for 14 days. Subsequently, after a 1-month washout, they were crossed over to the other group

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age of 20 t 60 years Confirmed diagnosis of primary progressive progressive MS No medical history of allergy to clarithromycin

Exclusion criteria

Exclusion criteria: Pregnancy or breast feeding patients Serious underlying medical conditions (e.g malignancy, renal and hepatic failure) Known hypersensitivity to clarithromycin and excipients Significant signs of depression

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: Before intervention and 2, 6, 8 weeks after intervention. Method of measurement: ELISA Kit.;Quality of life. Timepoint: before intervention and 2, 6, 8 weeks after intervention. Method of measurement: The quality of life questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid esmaeilzadeh-shahri

Islamic Azad University

navid.esmaeelzade@gmail.com+98 21 2264 0051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026